Primary outcome measure (mYPAS-SF)
The primary outcome measure, mYPAS-SF, was completed at baseline and at least one follow-up time point for 94 participants (86%), with all data included in the ITT analysis. Six participants (6%) were excluded from the PP analysis. The adjusted mean difference in mYPAS-SF scores for melatonin Adjusted mean difference in mYPAS-SF of melatonin compared with midazolam from the primary analysis models. (Mean [standard deviation]) mYPAS-SF scores and adjusted mean differences from the primary analysis model for each analysis population located in 